Department of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
MedStar Georgetown University Hospital, Medstar Transplant Hepatology Institute, Washington, DC, USA.
Hepatol Commun. 2022 Dec;6(12):3291-3298. doi: 10.1002/hep4.2094. Epub 2022 Sep 27.
Aortic stenosis (AS) is the most common valvular disease and is reported to be present in 2%-7% of people over the age of 65. Risk factors for aortic stenosis and NASH overlap; thus, as the population ages, there is an increased likelihood that patients undergoing liver transplantation evaluation may have severe aortic stenosis. There is a high mortality rate associated with cardiac surgeries in patients with cirrhosis. Further, there are no guidelines that assist in the decision making process for patients with cirrhosis and AS. In this review, we highlight key studies that compare transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in patients with cirrhosis. We propose an algorithm as to how to approach the patient with aortic stenosis and considerations unique to patients with cirrhosis (i.e., anticoagulation, EGD for variceal assessment; need to determine timing after TAVI before listing).
主动脉瓣狭窄(AS)是最常见的瓣膜疾病,据报道,65 岁以上人群中有 2%-7%存在这种疾病。主动脉瓣狭窄和 NASH 的风险因素重叠;因此,随着人口老龄化,接受肝移植评估的患者中可能有更多的严重主动脉瓣狭窄患者。肝硬化患者的心脏手术死亡率很高。此外,对于患有肝硬化和 AS 的患者,没有指导方针可以帮助做出决策。在这篇综述中,我们重点介绍了比较经导管主动脉瓣植入术(TAVI)与外科主动脉瓣置换术(SAVR)在肝硬化患者中的关键研究。我们提出了一种如何处理主动脉瓣狭窄患者的算法,并考虑到了肝硬化患者的独特情况(即,抗凝治疗,EGD 用于评估静脉曲张;需要确定 TAVI 后何时进行列表)。